A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of 4 new formulations of fentanyl transdermal patch in healthy participants after a single application for 72 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System

NCT00864565

Healthy

COMPLETED PHASE1

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971

Peer Review, Research

COMPLETED PHASE4

Relative Bioavailability of a Fentanyl Patch

NCT00857753

Pain

COMPLETED PHASE1

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System

NCT00650117

Healthy

COMPLETED PHASE1

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

NCT00648414

Healthy

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), 4-way crossover (participants will receive different interventions sequentially during the trial) study. The study will assess the pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) and relative bioavailability (the extent to which a drug or other substance becomes available to the body) of 4 new formulations of fentanyl transdermal patch, TDS-Concept 1 50 µg/h, TDS-Concept 2 50 µg/h, TDS-Concept 3 50 µg/h and TDS-Concept 4 100 µg/h compared with DUROGESIC fentanyl 50 µg/h in healthy participants after a single application. All participants will be randomly assigned to 1 of 8 possible treatment sequences. During the 4 single-application treatment periods, each transdermal patch will be worn, on a different application site on the lateral side of the upper arm, continuously for 72 hours. The treatment periods will be separated by a washout period (period when receiving no treatment) of at least 8 and no more than 14 days. The total study length is from 64 days to a maximum of 82 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment sequence 1 (AEBD)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 2 (BACE)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 3 (CBDA)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 4 (EDAC)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 5 (DECA)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 6 (EADB)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 7 (ABEC)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Treatment sequence 8 (BCAD)

Group Type EXPERIMENTAL

Treatment A: DUROGESIC (8.4 mg fentanyl)

Intervention Type DRUG

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

Intervention Type DRUG

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment A: DUROGESIC (8.4 mg fentanyl)

One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.

Intervention Type DRUG

Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)

One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Intervention Type DRUG

Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)

One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.

Intervention Type DRUG

Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)

One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Intervention Type DRUG

Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index (BMI; weight \[kg\]/height2 \[m\]2) between 18 and 30 kg/m2 (inclusive), and body weight not less than 50 kg
* Participants must utilize a medically acceptable method of contraception throughout the entire study period including the washout period and for 3 months (men) or 1 week (women) after the study is completed
* Men must not donate sperm from the first drug administration until 3 months after completion of the study
* Each participant will receive a test for opioid dependency. Only those participants that pass this challenge test will be allowed to continue in this study
* Non-smoker

Exclusion Criteria

* History of or current clinically significant medical illness, disease or condition that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results
* Clinically significant abnormal laboratorial values
* Clinically significant abnormal physical examination, vital signs or electrocardiogram (ECG)
* Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol, oral contraceptives and hormonal replacement therapy within 14 days before the first dose of the study drug is scheduled
* History of, or a reason to believe a participant has a history of drug or alcohol abuse within the past 5 years

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes